- Home
- CHI vs CRMD Comparison
CHI vs CRMD Comparison
Compare CHI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | CRMD |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.5M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | CHI | CRMD |
|---|---|---|
| Price | $10.86 | $11.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 186.2K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.09 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $9.70 | $5.60 |
| 52 Week High | $11.61 | $17.43 |
Technical Indicators
Market Signals| Indicator | CHI | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 62.82 |
| Support Level | $10.77 | $10.90 |
| Resistance Level | $10.95 | $12.10 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 81.73 | 83.59 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.